Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02851056 · ClinicalTrials.gov registry record · Early Phase 1
Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)
A Early Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 14
- Enrollment target
NCT02851056 is a Early Phase 1 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 14 participants.
The verdict
NCT02851056, a Early Phase 1 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to test what effects (good and bad) a new cancer vaccine will have on participants and their cancer, when administered before and after their autologous hematopoietic cell transplant (HCT). The name of the vaccine is called Dendritic Cell Survivin Vaccine (DC:AdmS). The vaccine is made using the participant's own blood cells. The vaccine will contain a virus called an adenovirus, similar the virus that causes the common cold. The virus has been changed so it cannot infect humans and cause infections. The vaccine will be prepared at Moffitt Cancer Center in the Cell Therapy Laboratory Facility.
Interventions
- BIOLOGICAL Prevnar 13
- BIOLOGICAL Survivin Vaccine
- PROCEDURE Autologous Hematopoietic Cell Transplantation
- DRUG Granulocyte-colony Stimulating Factor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2016-09-27 |
| Est. Completion | 2018-08-09 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02851056
The ClinicalTrials.gov registry entry for NCT02851056 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Prevnar 13 is the first listed.
NCT02851056 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02851056 about?
NCT02851056 is a clinical study titled "Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)". The purpose of this study is to test what effects (good and bad) a new cancer vaccine will have on participants and their cancer, when administered before and after their autologous hematopoietic cell transplant (HCT). The name of the vaccine is called Dendritic Cell Survivin Vaccine (DC:AdmS). The...
What is the current status of trial NCT02851056?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 14 participants. The study started on 2016-09-27. Estimated completion is 2018-08-09.
What interventions are being tested in trial NCT02851056?
The interventions under investigation include: Prevnar 13 (BIOLOGICAL), Survivin Vaccine (BIOLOGICAL), Autologous Hematopoietic Cell Transplantation (PROCEDURE), Granulocyte-colony Stimulating Factor (DRUG).
Who is sponsoring clinical trial NCT02851056?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.